1-9 of 9
emicizumab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding

Maureane Hoffman
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3736.
https://doi.org/10.1182/bloodadvances.2021004802
Published: 2021
Includes: Supplemental data
Journal Articles

First report of emicizumab use in a female patient with severe hemophilia A

Clinical Trials & Observations
Géraldine Verstraete, Catherine Lambert, Cedric Hermans
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2950–2952.
https://doi.org/10.1182/bloodadvances.2020002364
Published: 2020
Journal Articles

Laboratory monitoring of hemophilia A treatments: new challenges

Clinical Trials & Observations
Peter J. Lenting
Journal: Blood Advances
Blood Adv (2020) 4 (9): 2111–2118.
https://doi.org/10.1182/bloodadvances.2019000849
Published: 2020
Journal Articles

Total knee replacement with and without emicizumab: a unique comparison of perioperative management

Clinical Trials & Observations
Matthew S. Evans, Charles Davis, III, M. Elaine Eyster
Journal: Blood Advances
Blood Adv (2020) 4 (5): 855–857.
https://doi.org/10.1182/bloodadvances.2019001060
Published: 2020
Journal Articles

Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies

Angela C. Weyand, Veronica H. Flood, Jordan A. Shavit, Steven W. Pipe
Journal: Blood Advances
Blood Adv (2019) 3 (18): 2748–2750.
https://doi.org/10.1182/bloodadvances.2019000656
Published: 2019
Journal Articles

Emicizumab use in major orthopedic surgery

Clinical Trials & Observations
Craig D. Seaman, Margaret V. Ragni
Journal: Blood Advances
Blood Adv (2019) 3 (11): 1722–1724.
https://doi.org/10.1182/bloodadvances.2019000228
Published: 2019
Journal Articles

Emicizumab should be prescribed independent of immune tolerance induction

Sandra Le Quellec, Claude Negrier
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2783–2786.
https://doi.org/10.1182/bloodadvances.2018015859
Published: 2018
Journal Articles

Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance

Guy Young
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2780–2782.
https://doi.org/10.1182/bloodadvances.2018015842
Published: 2018
Journal Articles

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Clinical Trials & Observations
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Ryu Kasai, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami
Journal: Blood Advances
Blood Adv (2017) 1 (22): 1891–1899.
https://doi.org/10.1182/bloodadvances.2017006684
Published: 2017
Includes: Supplemental data